Vaccination to Reduce Antimicrobial Resistance Burden-Data Gaps and Future Research.

antimicrobial resistance (AMR) data gaps indirect effect study design vaccination

Journal

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
ISSN: 1537-6591
Titre abrégé: Clin Infect Dis
Pays: United States
ID NLM: 9203213

Informations de publication

Date de publication:
20 Dec 2023
Historique:
medline: 20 12 2023
pubmed: 20 12 2023
entrez: 20 12 2023
Statut: ppublish

Résumé

Antimicrobial resistance (AMR) poses an immediate danger to global health. If unaddressed, the current upsurge in AMR threatens to reverse the achievements in reducing the infectious disease-associated mortality and morbidity associated with antimicrobial treatment. Consequently, there is an urgent need for strategies to prevent or slow the progress of AMR. Vaccines potentially contribute both directly and indirectly to combating AMR. Modeling studies have indicated significant gains from vaccination in reducing AMR burdens for specific pathogens, reducing mortality/morbidity, and economic loss. However, quantifying the real impact of vaccines in these reductions is challenging because many of the study designs used to evaluate the contribution of vaccination programs are affected by significant background confounding, and potential selection and information bias. Here, we discuss challenges in assessing vaccine impact to reduce AMR burdens and suggest potential approaches for vaccine impact evaluation nested in vaccine trials.

Identifiants

pubmed: 38118013
pii: 7481752
doi: 10.1093/cid/ciad562
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

S597-S607

Informations de copyright

© The Author(s) 2023. Published by Oxford University Press on behalf of Infectious Diseases Society of America.

Déclaration de conflit d'intérêts

Potential conflicts of interest. The authors: No reported conflicts of interest. All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest.

Auteurs

Birkneh Tilahun Tadesse (BT)

International Vaccine Institute, Seoul, Republic of Korea.
Division of Clinical Pharmacology, Department of Laboratory Medicine, Karolinska Institutet, Karolinska University Hospital Huddinge, Stockholm, Sweden.
Center for Innovative Drug Development and Therapeutic Trials for Africa, College of Health Sciences, Addis Ababa University, Addis Ababa, Ethiopia.

Karen H Keddy (KH)

Independent Consultant, Johannesburg, South Africa.

Natasha Y Rickett (NY)

International Vaccine Institute, Seoul, Republic of Korea.

Aidai Zhusupbekova (A)

International Vaccine Institute, Seoul, Republic of Korea.

Nimesh Poudyal (N)

International Vaccine Institute, Seoul, Republic of Korea.

Trevor Lawley (T)

Wellcome Sanger Institute and Microbiotica, Cambridge, United Kingdom.

Majdi Osman (M)

Cambridge Institute of Therapeutic Immunology and Infectious Disease, University of Cambridge School of Clinical Medicine, Cambridge, United Kingdom.

Gordon Dougan (G)

Cambridge Institute of Therapeutic Immunology and Infectious Disease, University of Cambridge School of Clinical Medicine, Cambridge, United Kingdom.

Jerome H Kim (JH)

International Vaccine Institute, Seoul, Republic of Korea.
Seoul National University, College of Natural Sciences, Seoul, Republic of Korea.

Jung-Seok Lee (JS)

International Vaccine Institute, Seoul, Republic of Korea.

Hyon Jin Jeon (HJ)

International Vaccine Institute, Seoul, Republic of Korea.
Cambridge Institute of Therapeutic Immunology and Infectious Disease, University of Cambridge School of Clinical Medicine, Cambridge, United Kingdom.
Madagascar Institute for Vaccine Research, University of Antananarivo, Antananarivo, Madagascar.

Florian Marks (F)

International Vaccine Institute, Seoul, Republic of Korea.
Cambridge Institute of Therapeutic Immunology and Infectious Disease, University of Cambridge School of Clinical Medicine, Cambridge, United Kingdom.
Madagascar Institute for Vaccine Research, University of Antananarivo, Antananarivo, Madagascar.
Heidelberg Institute of Global Health, University of Heidelberg, Heidelberg, Germany.

Classifications MeSH